SHANGHAI – Upstart Beigene Co. Ltd. wowed observers last year when it landed two deals Merck Serono, a division of Merck KGaA, which licensed global rights to two of their preclinical oncology candidates for a combined value of close to $500 million. Out of the limelight, Beigene's momentum has not wavered. It has moved three oncology candidates into the clinic, the latest being Bruton tyrosine kinase (BTK) inhibitor, BGB-3111.